Clinical trials: Atrophy of Vagina
Vaginal Atrophy
A Pharmacokinetic Study of Vaginally and Intravenously Administered Oxytocin
This study aims to evaluate the uptake of oxytocin following intravaginal administration of Vagitocin 400IU over a period of 15 days and also to compare oxytocin bioavailability after vaginal and intravenous administration.
- Trial name
- NCT01975129
- Testing
- Vagitocin
- Where
- Sweden
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- PepTonic Medical AB
Genitourinary Syndrome of Menopause (GSM), Breast Cancer
Efficacy of Non-ablative Radiofrequency Combined With Pelvic Floor Muscle Training for Genitourinary Syndrome of Menopause in Breast Cancer Survivors (RF-SGM)
The goal of this clinical trial is to find out whether non-ablative radiofrequency (RF) applied together with pelvic-floor muscle exercises can ease vaginal dryness and other symptoms of genitourinary syndrome of menopause (GSM)…
- Trial name
- NCT07034976
- Testing
- Active Radiofrequency (Capenergy C500 UpGradeC200)
- Where
- Spain
- Volunteers
- 50 people
- Sponsor
- Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
Vaginal Atrophy
A Clinical Trial to Assess the Safety of 0.005 % Estriol Vaginal Gel in Hormone Receptor-Positive Postmenopausal Women With Early Stage Breast Cancer in Treatment With Aromatase Inhibitor in the Adjuvant Setting
This is a phase II, prospective, randomized, double-blind, placebo-controlled, international (Spain and Sweden) and multicentre study to explore the safety of 0.005% estriol vaginal gel in women with early stage breast cancer in…
- Trial name
- BLISSAFE (NCT02413008)
- Testing
- estriol
- Where
- 6 sites in Spain, Sweden
- Volunteers
- 61 people
- Sponsor
- ITF Research Pharma, S.L.U.
Genitourinary Syndrome of Menopause
Natural Topical Treatment for Vulvar and Vaginal Atrophy
Genitourinary syndrome of menopause (GSM) is a chronic and progressive syndrome characterized by a collection of genital and urinary signs and symptoms secondary to the state of hypoestrogenism related to menopause.
- Trial name
- NCT05871255
- Testing
- Zantogin® Gel
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Dr. Amjad Khan
Vaginal Atrophy
Study Evaluating Bazedoxifene/Conjugated Estrogen Combinations in Vasomotor Symptoms Associated With Menopause
The purpose of this study is to determine whether Bazedoxifine/conjugated estrogens are effective in the treatment of vaginal atrophy.
- Trial name
- NCT00238732
- Testing
- Bazedoxifene/Conjugated Estrogen
- Where
- 63 sites in United States
- Volunteers
- 650 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Vaginal Atrophy
A Clinical Clinical Observation of CO2 Fractional Laser in Female Vaginal Repair
1. Vaginal atrophy is the most common indication in the treatment of vaginal rejuvenation. Its main manifestation is vaginal relaxation syndrome, which may be the early symptom of female pelvic floor dysfunction.
- Trial name
- NCT04492176
- Testing
- CO2 fractional laser（ACUPULSE,Lumenis）
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Xijing Hospital
Vaginal Atrophy, Vulva; Atrophy
LASER and Radiofrequency for Treatment of Vaginal Vulvar Atrophy (VVA) in Women Treated for Breast Cancer (EPMLARF-arm2)
This is a randomized controlled trial to evaluate the use of LASER, Micro Ablative radiofrequency and topic promestriene to treat symptoms of vulvovaginal atrophy of women treated for breast cancer.
- Conditions
- Vaginal Atrophy, Vulva; Atrophy, Breast Cancer
- Trial name
- EPMLARF (NCT04081805)
- Testing
- LASER, Micro Ablative Radiofrequency, Promestriene
- Where
- Brazil
- Volunteers
- 195 people
- Sponsor
- Federal University of São Paulo
Genitourinary Syndrome of Menopause
Clinical and Cyto-histological Evaluation of Fractional CO2 Laser Treatment on Genito-Urinary Syndromes of Menopause Related to Vaginal Atrophy
Estrogen deficiency can occur naturally during menopause or as a secondary effect of various treatments for breast or pelvic cancer and can lead to very disabling vulvovaginal symptoms, since it is associated with an anatomical…
- Trial name
- ATROVENANS (NCT05151380)
- Testing
- CO2 laser MonaLisa Touch ®
- Where
- France
- Volunteers
- 75 people
- Sponsor
- Hopital Nord Franche-Comte
Menopause, Genitourinary Syndrome of Menopause
Examining Effects of Intrarosa in Women With Genitourinary Syndrome of Menopause/Vulvovaginal Atrophy
Tissues of the genitals of women are both androgen (testosterone) and estrogen dependent. The clitoris, vestibule, urethra, anterior vaginal wall, peri-urethral tissue, and pelvic floor all depend on androgens for normal…
- Conditions
- Menopause, Genitourinary Syndrome of Menopause, Vulvovaginal Atrophy, Menopause Syndrome
- Trial name
- NCT03782480
- Testing
- Intrarosa
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Center for Vulvovaginal Disorders
Vulvovaginal Atrophy
Vaginal Microbiota Among Postmenopausal Women
It is known that vaginal bacteria have an impact upon the health status of the host, in some cases protecting against infection and in other cases causing infection, depending on the bacterial types present.
- Trial name
- NCT01084616
- Where
- Canada
- Volunteers
- 16 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Vaginal Atrophy
A Randomized Controlled Phase 2 Study to Determine Lowest Efficacious Dose of Ovestin in Vulvar and Vaginal Atrophy
This is a prospective, multicenter, randomized, double-blind, placebo-controlled, dose-de-escalation study whose purpose is to establish the lowest efficacious dose.
- Trial name
- DOVE (NCT04159493)
- Testing
- Estriol
- Volunteers
- healthy volunteers welcome
- Sponsor
- Aspen USA Inc
Vaginal Atrophy
Non-Interventional Multicentre Post-market Study of Ectoin® Vaginal Gel for Symptomatic Treatment of Vaginal Atrophy
The goal of this multi-centre, prospective, open label, single arm, observational post-market clinical follow-up study (§23b of the MPG (German Medical Act) MDD 93/42/EEC and ISO14155:2020) is to investigate and evaluate the…
- Trial name
- EIC01-PMCF (NCT04910906)
- Testing
- Ectoin® Vaginal Gel
- Where
- Germany
- Volunteers
- 155 people
- Sponsor
- Bitop AG
Atrophy, Vaginal Atrophy
Prospective, Open-Label, Single-Center, Non-Comparative Study to Assess the Use of Pixel CO2 Laser System (FemiLift) in the Treatment of Vulvovaginal Atrophy (VVA) in Postmenopausal Female Subjects
The purpose of this study is to assess the use of the Alma CO2 Pixel FemiLift™ in the treatment of VulvoVaginal Atrophy (VVA) in postmenopausal female subjects.
- Conditions
- Atrophy, Vaginal Atrophy, Genital Diseases, Female
- Trial name
- NCT02747641
- Testing
- Pixel CO2 Laser System
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Alma Lasers Inc.
Vaginal Atrophy, Sexual Dysfunction
Hybrid Fractional Laser for Symptoms of Genitourinary Syndrome of Menopause
This multi-center clinical trial will evaluate the safety and long-term efficacy of hybrid fractional 2940 nm and 1470 nm lasers for treatment of symptoms of Genitourinary Syndrome of Menopause.
- Conditions
- Vaginal Atrophy, Sexual Dysfunction, Dyspareunia, Vaginal Dryness
- Trial name
- NCT03178825
- Testing
- Hybrid Fractional Laser
- Where
- 6 sites in United States
- Volunteers
- 60 people
- Sponsor
- Sciton
Pelvic Organ Prolapse, Urinary Incontinence
Vaginal Estradiol Use in Pessary Care
The primary outcome of this study compare the rate of pessary discontinuation at 6 months post-pessary fitting in women using vaginal estradiol versus those not using vaginal estradiol.
- Conditions
- Pelvic Organ Prolapse, Urinary Incontinence, Pessary Ulcer of Vagina, Vaginal Atrophy
- Trial name
- NCT05458375
- Testing
- Estradiol vaginal cream
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- University of South Florida
Atrophic Vaginitis, Menopause
Vaginal Progesterone Versus Placebo for the Treatment of Vaginal Atrophy
Atrophic vaginitis affects the majority of post-menopausal women. It is characterized by dryness and inflammation of the vagina, with thinning of the vaginal tissues.
- Conditions
- Atrophic Vaginitis, Menopause, Vulvovaginal Atrophy
- Trial name
- NCT02460302
- Testing
- Vaginal progesterone
- Where
- Canada
- Sponsor
- Mount Sinai Hospital, Canada
Menopause
The Effects of a Novel Probiotic Supplement on Menopausal Symptoms and Bone Health
This Phase II study is designed to evaluate the potential effects of a novel probiotic supplement on the severity of global menopause symptoms (e.g., psychological, somatic, urogenital symptoms) and on bone health in…
- Trial name
- MPS (NCT04001088)
- Testing
- Probiotic
- Where
- 5 sites in United States
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- Lallemand Health Solutions
Dyspareunia
Fractional CO2 Laser Therapy Versus 4% Topical Lidocaine Gel for Dyspareunia in Breast Cancer Survivors
This trial seeks to determine if therapy with a CO2 laser to the vagina is more effective than lidocaine to the opening of the vagina before intercourse to reduce painful intercourse in women who are breast cancer survivors.
- Trial name
- BCLS (NCT03257670)
- Testing
- 4% Topical Lidocaine Gel, CO2RE fractional laser therapy
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- University of Cincinnati
Vaginal Atrophy, Urinary Incontinence,Stress
Low-level Laser Therapy for Genitourinary Syndromes and Stress Urinary Incontinence
Genitourinary syndrome of menopause (GSM) and stress urinary incontinence (SUI) are common for women. Low-level laser therapy (LLLT) was applied for wound healing, but there was no study regarding treatment effect of GSM and SUI.
- Trial name
- NCT06136975
- Testing
- Low-level laser therapy
- Where
- Taiwan
- Volunteers
- 41 people
- Sponsor
- National Taiwan University Hospital
Vulvar Atrophy, Breast Cancer
Vaginal Prasterone In Vaginal Atrophy In Breast Cancer Survivors
VAGINAL PRASTERONE in the treatment of VAGINAL ATROPHY IN PATIENTS WITH BREAST CANCER TREATMENT WITH AROMATASE INHIBITORS (VIBRA STUDY)
- Conditions
- Vulvar Atrophy, Breast Cancer, Genitourinary Syndrome of Menopause
- Trial name
- VIBRA (NCT04705883)
- Testing
- Prasterone (DHEA), Micronized
- Where
- Spain
- Volunteers
- 10 people
- Sponsor
- Hospital Clinic of Barcelona